Private Eye’s “High Principals” is a long-running investigative and satirical column devoted to the management of universities and other higher education institutions, particularly the conduct of vice-chancellors, principals, university executives and governing bodies. Unsurprisingly, Cambridge is making regular appearances.

For decades, the Medical Research Council (MRC) research units have been an important part of Cambridge’s scientific reputation. They have provided specialist research facilities, supported generations of scientists and contributed to advances in medical science. Their work has depended not only on distinguished academic researchers but also on experienced technical, administrative and professional staff whose expertise is essential to the functioning of complex research programmes.

The future of these institutions was placed in jeopardy following the MRC’s decision to abandon its traditional system of direct funding for research units.

A funding decision with far-reaching consequences

The MRC’s replacement of its established unit-funding arrangements with a competitive system of Centres of Research Excellence has created considerable distress and dismay.

Under the previous arrangements, the MRC provided long-term core funding to a number of established research Units, enabling them to develop and sustain distinctive areas of scientific expertise over many years. Funding was generally awarded on a continuing basis, subject to periodic scientific review, normally every five years. This approach provided stability and continuity, supporting not only individual research programmes but also permanent research teams, specialist technical expertise, infrastructure and facilities. It allowed Units to pursue long-term programmes of fundamental and applied research, including work whose scientific or clinical benefits might take many years to emerge.

The MRC decided to replace this established system with a competitive model of Centres of Research Excellence (CoREs), under which funding would be awarded through open competition to centres proposing research programmes addressing significant scientific and health challenges. The new Centres would receive time-limited funding, potentially for up to 14 years, with an assessment during the funding period. Rather than supporting established Units through their existing arrangements, the new model would enable research groups and institutions to compete for substantial funding on the basis of their proposed scientific programmes and their capacity to deliver research excellence.

The rationale for the change, as presented by the MRC, was to make its major research investments more strategically directed, flexible and responsive to emerging scientific opportunities and health priorities. However, the change also represented a fundamental shift away from the principle of sustaining long-term research capacity and established scientific communities towards a more competitive, time-limited and challenge-led funding model.

The new arrangements do not provide the same comprehensive financial support as the previous model. In particular, the funding does not necessarily cover the extensive infrastructure and support staff required to sustain a major research institution.

Cambridge hosted six of the MRC units: Epidemiology, Mitochondrial Biology, Cognition and Brain Sciences, Toxicology, Metabolic Diseases and Biostatistics. The University Council quickly announced that it could not absorb all 550 staff and their facilities in one go, given the university’s own financial position.

It  therefore faced difficult decisions about which activities to preserve, how to reorganise its research institutions and what would happen to hundreds of employees. These were not simply administrative decisions. They concerned the future of established research communities and the livelihoods of people who had devoted much of their working lives to scientific research.

The human cost of restructuring

The first to undergo transition was the MRC Epidemiology Unit. This went badly with the University seemingly in breach of its obligations under employment law. The Board of Scrutiny in its 31st Report wrote:

Concerns about process, governance and transparency are also reflected in the Board’s consideration of the organisational change arising from the subsuming of Medical Research Council (MRC) Units into university departments. Following the MRC’s decision to withdraw core Unit funding from 2025, the MRC Epidemiology Unit became the first at Cambridge to undergo this process. In April 2026, it transitioned to IMS Epidemiology (Institute of Metabolic Science Epidemiology), part of the Institute of Metabolic Science in the School of Clinical Medicine. According to data seen by the Board, this resulted in 29 redundancies, in addition to other  staff departures.

 Information received by the Board suggested significant deficiencies in the process, which was overseen by a Project Board. These include concerns about whether consultation met statutory requirements, the late and incomplete release of key documentation, weaknesses in the business case, limited financial transparency, and the decision to run collective and individual consultation processes concurrently. As further Units—and potentially other Departments—undergo similar transitions, it is important that these issues be addressed.  The Board was reassured to note that a lessons learned exercise has been undertaken

Unfortunately, lessons do not seem to have been learned. The same problems are recurring with the MRC Cognition and Brain Sciences Unit, which is currently going through the same process as MRC Epidemiology — with the same deficiencies. 

The HR division does not seem to be doing any better second time round. 

Where was institutional responsibility?

Cambridge is one of the world’s leading research universities. Its reputation rests not simply on the achievements of individual academics but also on the institutions, facilities and professional teams that enable scientific work to flourish.

The University cannot reasonably measure the value of a research unit solely by the income it generates or the funding it attracts. There is a wider institutional responsibility to protect valuable research capabilities, maintain continuity and treat employees fairly.

For sure, the MRC funding changes presented Cambridge with a difficult challenge, as it has so many MRC Units. However, the existence of that challenge does not remove the University’s responsibility for the way it responds. It was happy take teh funding when it was plentiful. It should not push all the risk onto the staff is funding becomes trickier.

Lessons that Cambridge must address

The transition of the MRC units should prompt a serious and independent examination of the University’s decision-making processes.

Such an examination should consider the adequacy of financial planning, the transparency of management decisions, the effectiveness of staff consultation and the extent to which alternative employment arrangements were explored. It should also assess the long-term consequences for research quality, training, specialist facilities and Cambridge’s international scientific standing.

The central issue is not whether the University could have avoided every consequence of the MRC’s funding decision. That may not have been possible. The issue is whether the University did everything reasonably possible to protect the people and research capabilities entrusted to it.

Cambridge has built its reputation over centuries through the work of generations of scientists. That reputation cannot be sustained simply by preserving buildings, departments and institutional  names. It depends on people, expertise, continuity and a culture in which scientific excellence is valued.

If the restructuring of the MRC units results in the unnecessary loss of experienced staff and irreplaceable research capabilities, the damage may prove far greater than the immediate savings.

The question Cambridge must now answer is whether it has managed a difficult transition responsibly — or whether, in the process, it has put a valuable part of its scientific heritage at risk.